Close Menu

NEW YORK — Cellectricon said on Tuesday that it has signed an agreement to use StressMarq Biosciences' reagents for its neurodegenerative research.

Mölndal, Sweden-based Cellectricon provides drug discovery services, with a focus on chronic pain and neurodegenerative disease. Among its areas of research is the spread of neurodegenerative disease-associated peptides, such as amyloid-beta peptides, tau, and alpha-synuclein, that characterizes Alzheimer's disease and Parkinson's disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Oct
06
Sponsored by
10x Genomics

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by irreversible scarring of the distal lung, leading to respiratory failure. 

Oct
13
Sponsored by
Lexogen

This webinar will outline the use of targeted protein degradation (TPD) to understand transcriptional processes at a high kinetic resolution.